TransMedics (TMDX) EPS (Weighted Average and Diluted) (2020 - 2026)

TransMedics' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at $0.2 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 71.43% year-over-year to $0.2; the TTM figure through Mar 2026 stood at $4.37 (up 218.98% YoY), while the FY2025 annual figure was $4.87, up 382.18% from the prior year.
• EPS (Weighted Average and Diluted) was $0.2 for Q1 2026 at TransMedics, down from $2.59 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.59 in Q4 2025 to a low of -$0.78 in Q3 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.24 across 5 years, with a median of $0.12 in 2023.
• The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) slumped 212.0% in 2023, then jumped 1266.67% in 2024.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.2 in 2022, then surged by 160.0% to $0.12 in 2023, then surged by 66.67% to $0.2 in 2024, then jumped by 1195.0% to $2.59 in 2025, then slumped by 92.28% to $0.2 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.2 (Q1 2026), $2.59 (Q4 2025), and $0.66 (Q3 2025), per Business Quant data.